What is the role of beta histidine (histidine) and Stemtil (prochlorperazine) in patients with traumatic subarachnoid hemorrhage (SAH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Beta Histidine and Stematil in Traumatic SAH

Neither beta histidine (betahistine) nor Stematil (prochlorperazine) have any established role in the management of traumatic subarachnoid hemorrhage, and their use is not supported by any guideline or evidence-based recommendation for this condition.

Why These Medications Are Not Indicated

Betahistine

  • Betahistine is a histamine analog primarily used for vestibular disorders like Ménière's disease and vertigo 1
  • No guidelines for traumatic SAH mention betahistine as a treatment option 2, 3
  • There is no evidence that betahistine addresses any of the critical complications of traumatic SAH including rebleeding, delayed cerebral ischemia, vasospasm, hydrocephalus, or seizures 2, 4

Prochlorperazine (Stematil)

  • Prochlorperazine is an antiemetic and antipsychotic medication used primarily for nausea and vomiting 1
  • No SAH guidelines recommend prochlorperazine for any aspect of traumatic SAH management 2, 3
  • While nausea and vomiting are common symptoms of SAH, prochlorperazine is not specifically recommended in the evidence-based management protocols 4, 5

What IS Recommended for Traumatic SAH

Immediate Priorities

  • Transfer to a high-volume center (>35 SAH admissions/year) with neurocritical care capabilities 3, 6
  • Blood pressure control to avoid severe hypotension, hypertension, and BP variability 3, 6
  • Urgent CSF diversion if acute symptomatic hydrocephalus develops 3
  • Emergency reversal of anticoagulants if applicable 3

Evidence-Based Pharmacotherapy

  • Nimodipine 60 mg orally every 4 hours for 21 consecutive days is the ONLY medication with proven benefit, starting within 96 hours of hemorrhage onset 3, 6, 1, 4
  • Maintain euvolemia rather than inducing hypervolemia 3, 6
  • Avoid prophylactic anticonvulsants (particularly phenytoin) as they are associated with worse outcomes 2, 3, 7

Medications to AVOID

  • Routine statins, intravenous magnesium, and endothelin antagonists have not improved outcomes 3, 1
  • Prophylactic triple-H therapy (hypervolemia, hypertension, hemodilution) should be avoided 6
  • Phenytoin for seizure prophylaxis is associated with excess morbidity and mortality 3, 7

Clinical Pitfall

The most common error would be using symptomatic medications like antiemetics or vestibular agents when the focus should be on evidence-based neuroprotection with nimodipine and prevention of life-threatening complications 3, 1, 5. If nausea requires treatment, this should be addressed as a supportive measure, but it is not a primary therapeutic target in traumatic SAH management 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Minimal Subarachnoid Hemorrhage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Subarachnoid Hemorrhage with Markedly Elevated Troponin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.